Navigation Links
Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential
Date:12/10/2009

es on a "drug liking" scale.

The subjects reported neutral "drug liking" scores for placebo and positive "drug liking" scores for zolpidem and ketamine, which confirmed study validity. The subjective effects of the 20 mg lorcaserin dose were similar to those of placebo. "Drug liking" was significantly lower for the 40 mg and 60 mg lorcaserin doses as compared to zolpidem and ketamine, and subjects demonstrated significant disliking of these supratherapeutic doses of lorcaserin compared to placebo. The subjects' willingness to take lorcaserin again for recreational purposes was significantly lower for 40 mg and 60 mg doses as compared to placebo.

Data from the trial demonstrate that the risk for abuse associated with lorcaserin is very low and less than that of zolpidem or ketamine. At the supratherapeutic doses, lorcaserin was associated with distinct, primarily negative, subjective effects. Although the majority of subjects who took lorcaserin at the supratherapeutic doses in this trial reported adverse events, most often headache, only two subjects withdrew from the trial because of an adverse event.

About Lorcaserin

Lorcaserin is a novel single agent that represents the first in a new class of selective serotonin 2C receptor agonists. The serotonin 2C receptor is expressed in the brain, including the hypothalamus, an area involved in the control of appetite and metabolism. Stimulation of this receptor is strongly associated with feeding behavior and satiety. Arena has patents that cover lorcaserin in the US and other jurisdictions, which in most cases are capable of continuing into 2023 without taking into account any patent term extensions or other exclusivity Arena might obtain.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central ner
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
2. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
3. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
4. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
5. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
6. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
7. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
8. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
9. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. Tumor Eradication Article Published by Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... million milestone payment from Biogen Idec related to advancing ... in infants with spinal muscular atrophy (SMA).  ... Rx, is a randomized, double-blind, sham-procedure controlled thirteen ... The study will evaluate the efficacy and safety of ...
(Date:3/5/2015)... -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... company serving the pharmaceutical, biotechnology, and medical device industries, ... announced its financial results for the fourth quarter and ... , Net Revenues Increased 21.3% Year Over Year ... Grew 17.7% Year Over Year to $140.5 Million ...
(Date:3/5/2015)... , March 5, 2015  As the ... of regulations, Ethics & Compliance professionals are placing ... a new survey issued today by LRN, the ... education. An overwhelming majority of respondents expressed that ... most important component of E&C training programs (57%), ...
Breaking Medicine Technology:Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 2Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 3Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 4Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 2Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 3
... proof of concept for company,s first-in-class SERM designed ... with hormone therapy--CAMBRIDGE, Mass., March 24 Radius ... has been dosed in the company,s proof-of-concept Phase ... receptor modulator (SERM) undergoing clinical evaluation for treatment ...
... Own Power in Health Care Decisions?CHARLOTTE, N.C., March 24 ... vibrant and healthy life at any age, or to ... & Symposium may have the answers right in your ... year,s premier health and wellness event in the queen ...
Cached Medicine Technology:Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes 2Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes 3Anti-Aging Expo & Symposium Showcases in Charlotte on March 28th 2
(Date:3/6/2015)... (PRWEB) March 06, 2015 Ticket Down is ... Portland, Oregon at the Moda Center. After being ... Garth Brooks is showing no signs of letting up on ... country legend and his wife, Trisha Yearwood, to venues around ... be bringing their critically acclaimed tour to the Moda Center ...
(Date:3/6/2015)... As the Muscular Dystrophy Association continues to enhance ... hired two new Scientific Program Officers, Amanda Haidet-Phillips, Ph.D ... Grace Pavlath, Ph.D, who joined MDA late last year ... together will lead MDA as it accelerates new front-line ... types of neuromuscular and motor neuron diseases. ...
(Date:3/6/2015)... US Sports Football Camps expands its network ... non-contact specialty camps and one contact football camp. The ... located at Bowie State University and Riverdale Baptist School. ... speed and strength of football athletes. The contact football ... Graves, former quarterback in the Canadian Football League, as ...
(Date:3/6/2015)... California (PRWEB) March 06, 2015 Johnson ... million jury verdict on March 5, 2015 in Superior ... According to court documents, a jury of 12 awarded ... suffered from being implanted with an Ethicon TVT Abbrevo ... nine men and three women also awarded $5 million ...
(Date:3/6/2015)... GA (PRWEB) March 06, 2015 ... announced the release of a Clostridium Difficile (C ... providers. The C Diff use case is the ... that span hospital acquired infections, chronic conditions, and ... platform, the C Diff solution flags at risk ...
Breaking Medicine News(10 mins):Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 2Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 4Health News:US Sports Camps to Host Three New Football Camps in Maryland 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2
... Ala., May 27 Leading fitness social network and tracking ... name to DailyBurn , effective immediately.In just ... community of more than 125,000 members, who have, depending on ... gained an average of 5.75 lbs of muscle using DailyBurn,s ...
... - New national survey reveals insights on treatment ... treatmentROCKLAND, Mass. and NEW YORK, May 27 ... with EMD Serono, today released findings from a ... Outlook on Emerging Therapies" in conjunction with the ...
... Practical Insights on Physician Engagement, Career SuccessSCOTTSDALE, Ariz., ... Corporation, whose Fusionfx solution suite aggregates ... single, clinically relevant views of patient information, today ... papers documenting the increasing involvement of healthcare chief ...
... at "A Chocolat au Vin Affair," St. Jude Inaugural Gala with ... 2009, 8:00pm, New York City. , ... (PRWEB) May ... the fight against childhood cancer by supporting St. Jude Children,s Research ...
... ), a comprehensive New Jersey anti-poverty charity, is experiencing an increase ... individual gifts -- Eva,s Village, Paterson, New Jersey, seeks additional funding ... ... (PRWEB) May 27, 2009 -- Eva,s Village describes an increase ...
... reducing their healthcare and insurance expenses during a hard-hitting ... ... Net implemented an across-the-board increase in California Medicare supplement insurance plan ... new ways to maximize healthcare dollars and minimize expenses says MedicareSupplementPlans.com., ...
Cached Medicine News:Health News:Gyminee Raises 525K and Relaunches as DailyBurn 2Health News:Multiple Sclerosis - What Are People With MS and Their Health Care Providers Really Thinking? 2Health News:Multiple Sclerosis - What Are People With MS and Their Health Care Providers Really Thinking? 3Health News:Multiple Sclerosis - What Are People With MS and Their Health Care Providers Really Thinking? 4Health News:Multiple Sclerosis - What Are People With MS and Their Health Care Providers Really Thinking? 5Health News:Carefx's Newest White Paper Illuminates Healthcare CIOs' Growing Role in Operations, Strategic Thinking and IT Project Decision Making 2Health News:Carefx's Newest White Paper Illuminates Healthcare CIOs' Growing Role in Operations, Strategic Thinking and IT Project Decision Making 3Health News:Trusted Translations Launches "Translation for St. Jude" Initiative at St. Jude Gala in New York 2Health News:Trusted Translations Launches "Translation for St. Jude" Initiative at St. Jude Gala in New York 3Health News:Trusted Translations Launches "Translation for St. Jude" Initiative at St. Jude Gala in New York 4Health News:Eva's Village, a Comprehensive New Jersey Anti-Poverty charity, Seeks Additional Funding to Meet the Increasing Need Along with a Decline in Donations 2Health News:Eva's Village, a Comprehensive New Jersey Anti-Poverty charity, Seeks Additional Funding to Meet the Increasing Need Along with a Decline in Donations 3Health News:Eva's Village, a Comprehensive New Jersey Anti-Poverty charity, Seeks Additional Funding to Meet the Increasing Need Along with a Decline in Donations 4Health News:Eva's Village, a Comprehensive New Jersey Anti-Poverty charity, Seeks Additional Funding to Meet the Increasing Need Along with a Decline in Donations 5Health News:Seniors Seek to Reduce Healthcare Costs as Premiums Increase Says MedicareSupplementPlans.com 2
The HEMOCHRON Model 401 is a portable, single-well whole blood coagulation monitoring instrument. The 401 provides on-screen plasma equivalent PT and APTT test results....
... a revolutionary scientific breakthrough for controlling unsightly ... Cream permits you to spot reduce in ... can rid yourself of those unwanted lumps ... to your thigh, waist, tummy, or chin ...
... G5 Contour is a non-invasive massage ... nodes and the circulatory system. Extraordinary ... G5 Directional-Stroking action, which combines vertical ... and comfortable percussion, gyratory massage, deep ...
The Ritter 204 Manual Exam Table. Featuring the latest in design, comfort and functionality in a manual exam table, it truly offers efficient patient care....
Medicine Products: